Company Description
Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States.
It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.
The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis.
In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain.
The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Nov 10, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Indranil Dey |
Contact Details
Address: 360 Massachusetts Avenue, Suite 203 Acton, Massachusetts 01720 United States | |
| Phone | (978) 631-0152 |
| Website | bluejaydx.com |
Stock Details
| Ticker Symbol | BJDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001704287 |
| CUSIP Number | 095633103 |
| ISIN Number | US0956333019 |
| Employer ID | 47-3552922 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Indranil Dey | Principal Financial, Accounting and Executive Officer, President, Chief Executive Officer and Director |
| Dr. Jason Cook | Chief Technology Officer |
| Les DeLuca | Vice President of Operations |
| Eryn Graham | Marketing Manager |
| Kevin Vance | Chief Commercial Officer |
| Mark W. Feinberg | Chief Medical Advisor |
| Dr. Mark W. Feinberg M.D. | Chief Medical Advisor |
| Ryan McSeveney | Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 5, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 2, 2024 | 8-K | Current Report |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 4, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 3, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 2, 2024 | 8-K | Current Report |
| Dec 29, 2023 | 424B4 | Prospectus |
| Dec 27, 2023 | EFFECT | Notice of Effectiveness |